pharma · Metachromatic Leukodystrophy (MLD) · Mucopolysaccharidosis type I, Hurler Syndrome
ORCHARD THERAPEUTICS
Orchard Therapeutics (Netherlands) B.V.
ORCHARD THERAPEUTICS clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- London, GB
- Employees
- 12
- Programs
- 5
- Drugs
- 12
- Patents
- 0
ORCHARD THERAPEUTICS projects
5 ClinicalTrials.gov programs sponsored by ORCHARD THERAPEUTICS.
ORCHARD THERAPEUTICS has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Libmeldy 2-10 x 10^6 cells/mL dispersion for infusion
Orchard Therapeutics (Netherlands) B.V.
Metachromatic Leukodystrophy (MLD)
1 trial -
Libmeldy 2-10 x 10^6 cells/mL dispersion for infusion
Orchard Therapeutics (Netherlands) B.V.
Metachromatic Leukodystrophy (MLD) is an autosomal recessive disorder caused by mutations
1 trial -
OTL-203-02
Orchard Therapeutics (Netherlands) B.V.
Mucopolysaccharidosis type I, Hurler Syndrome
1 trial -
Libmeldy 2-10 x 10^6 cells/mL dispersion for infusion
Orchard Therapeutics (Netherlands) B.V.
Metachromatic Leukodystrophy (MLD)
1 trial -
TigetT10_MPSIH
Orchard Therapeutics (Netherlands) B.V.
Mucopolysaccharidosis type I Hurler
1 trial
Frequently asked questions
How many clinical projects does ORCHARD THERAPEUTICS have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.